Lannett Company, Inc.  

(Public, NYSE:LCI)   Watch this stock  
Find more results for LCI
22.90
-0.65 (-2.76%)
Feb 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 22.40 - 23.55
52 week 16.75 - 39.99
Open 23.35
Vol / Avg. 0.00/1.21M
Mkt cap 828.13M
P/E     -
Div/yield     -
EPS -0.64
Shares 37.19M
Beta 2.24
Inst. own 92%
Feb 1, 2017
Q2 2017 Lannett Company Inc Earnings Release (Estimated)
Jan 20, 2017
Lannett Company Inc Annual Shareholders Meeting (Estimated)
Jan 18, 2017
Lannett Company Inc Annual Shareholders Meeting
Dec 14, 2016
Lannett Company Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Dec 13, 2016
Lannett Company Inc at Guggenheim Boston Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 4.79% 7.92%
Operating margin 20.07% 22.57%
EBITD margin - 40.66%
Return on average assets 1.88% 3.95%
Return on average equity 6.16% 8.80%
Employees 1,149 -
CDP Score - -

Address

9000 State Rd
PHILADELPHIA, PA 19136-1615
United States - Map
+1-215-3339000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Officers and directors

Jeffrey Farber Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Arthur P. Bedrosian J.D. Chief Executive Officer, Director
Age: 69
Bio & Compensation  - Reuters
Martin P. Galvan CPA Chief Financial Officer, Vice President - Finance, Treasurer
Age: 63
Bio & Compensation  - Reuters
Kristie Stephens Chief Compliance Officer, Vice President
Bio & Compensation  - Reuters
Robert Ehlinger Vice President - Logistics, Chief Information Officer
Age: 58
Bio & Compensation  - Reuters
Kevin R. Smith Vice President - Sales and Marketing
Age: 55
Bio & Compensation  - Reuters
John M Abt Vice President of Quality
Age: 51
Bio & Compensation  - Reuters
Rohit Desai Vice President of New Product Strategy
Age: 74
Bio & Compensation  - Reuters
John Kozlowski Vice President Financial Operations and Corporate Controller
Bio & Compensation  - Reuters
Albert Paonessa III Director
Age: 55
Bio & Compensation  - Reuters